1. Change in management of elevated blood pressure 2. Estimated glomerular filtration rate (eGFR) thresholds that trigger treatment dose adjustments were revised 3. All renal adverse events will be followed until resolution or stabilization 4. Exclusion criteria revised to ensure adequate washout of previously used investigational products 5. Addition of a maximum permitted duration of acute NSAID use 6. Clarified that the use of lipid-lowering agents and antimalarials are considered part of standard of care therapy 7. Clarified that study subjects will be stratified according to whether their kidney biopsies demonstrate pure Class V or not. 8. Addition of secondary endpoint for presence or absence of active urinary sediment

1. The name of the Sponsor changed from Vifor International to Aurinia Pharmaceuticals Inc. Responsible personnel contact details were updated accordingly. 2. Inclusion/Exclusion Criteria: - Malignancy exclusion criterion clarified - The requirements for birth control were strengthened 3. Change in electrocardiogram (ECG) assessments 4. MMF dosing description clarified 5. Steroid dosing clarified 6. Addition of window for steroid taper 7. Permissibility of complete steroid withdrawal clarified 8. Voclosporin storage conditions updated 9. Change in size of blister wallet 10. Treatment for overdose clarified 11. Additional PK assessments added for exploratory purposes 12. Samples for biomarker assessment added 13. Addition of change from baseline parameter for QTcF measurement 14. Updated definitions of SAEs 15. Revised pregnancy reporting and management procedures 16. Addition of section regarding discontinuation of study drug due to an AE 17. Additional stratification parameter added 18. Statistical section clarified 19. Assessment of Systemic Lupus Erythematosus Disease Activity Index reduced 20. Addition of Schedule of Assessments 21. Protocol visits and unscheduled visits clarified 22. 24 hr urine collection added to Day 0, Week 24 and Week 48 23. Addition of serum pregnancy test at end of study 24. Urinalysis and blood chemistry clarified 25. Total amount of blood collected clarified 26. Physical examination clarified 27. Withdrawal procedures clarified 28. Screening visits revised 29. Data Safety Monitory Board responsibilities and procedures clarified 30. Informed consent process clarified 31. Blood pressure measurement clarified 32. Editorial Changes made to improve readability and clarity

1. Inclusion/exclusion criteria - clarified Class III proteinuria to more accurately reflect active Class III lupus nephritis - Clarified kidney biopsy criteria, if a subject has not had a recent kidney biopsy, one may be performed prior to randomization - Severe viral infections was defined - Addition of acceptable contraception methods - Clarified route of cyclophosphamide prohibited - Clarified use of biologic agents - Addition of prohibited medications - Addition of treatment restrictions for P-gp substrates and inhibitors 2. Clarified MMF dosing 3. Clarified Steroid dosing 4. Clarified study assessments after discontinuation due to pregnancies 5. Clarified kidney biopsy SAE reporting 6. Clarified subjects lost to follow-up 7. Clarified primary endpoint to include eGFR ≥60 mL/min/1.73m2 8. Clarified emergency unblinding procedures 9. Clarified process for patients with eGFR decreases >20-30% 10. Clarified total amount of blood collected 11. Clarified required lab test results at time of enrolment 12. Various editorial changes made throughout to improve readability and clarity